Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
CTR20171428Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Dec 2017; status: completed.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on CTR20171428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171428.